MicroRNA-26a/b directly regulate La-related protein 1 and inhibit cancer cell invasion in prostate cancer

International Journal of Oncology

Volumn 47, Issue 2, 2015, Pages 710-718

  Kato, Mayuko ^a   Goto, Yusuke ^a   Matsushita, Ryosuke ^b   Kurozumi, Akira ^a   Fukumoto, Ichiro ^a   Nishikawa, Rika ^a   Sakamoto, Shinichi ^a   Enokida, Hideki ^b   Nakagawa, Masayuki ^b   Ichikawa, Tomohiko ^a   Seki, Naohiko ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

LARP1; MicroRNA; MiR 26a; MiR 26b; Prostate cancer; Tumor suppressor

Indexed keywords

LA RELATED PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 26A; MICRORNA 26B; PROSTATE SPECIFIC ANTIGEN; PROTEIN; RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; AUTOANTIGEN; MIRN26A MICRORNA, HUMAN; RIBONUCLEOPROTEIN; SS-B ANTIGEN;

3' UNTRANSLATED REGION; ARTICLE; BINDING SITE; CANCER CELL; CELL INVASION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUCIFERASE ASSAY; LUMINESCENCE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RIBOSOME; RNA ISOLATION; RNA TRANSPORT; SIGNAL TRANSDUCTION; WESTERN BLOTTING; XTT ASSAY; AGED; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; TUMOR INVASION;

3' UNTRANSLATED REGIONS; AGED; AUTOANTIGENS; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RIBONUCLEOPROTEINS;

EID: 84932643911     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.3043     Document Type: Article

References (44)

1. S iegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65: 5-29, 2015.
2. Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B and Visakorpi T: Castration-resistant prostate cancer: From new pathophysiology to new treatment targets. Eur Urol 56: 594-605, 2009.
3. S turge J, Caley MP and Waxman J: Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat Rev Clin Oncol 8: 357-368, 2011.
4. Carthew RW and Sontheimer EJ: Origins and Mechanisms of miRNAs and siRNAs. Cell 136: 642-655, 2009.
5. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
6. Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 9: 102-114, 2008.
7. H obert O: Gene regulation by transcription factors and microRNAs. Science 319: 1785-1786, 2008.
8. Friedman RC, Farh KK, Burge CB and Bartel DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105, 2009.
9. Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol 27: 5848-5856, 2009.
10. K ojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, et al: Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106: 405-413, 2012.
11. K ojima S, Enokida H, Yoshino H, Itesako T, Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, et al: The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting GOLM1 in prostate cancer. J Hum Genet 59: 78-87, 2014.
12. Nishikawa R, Goto Y, Sakamoto S, Chiyomaru T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell migration and invasion via targeting of LASP1 in prostate cancer. Cancer Sci 105: 802-811, 2014.
13. Nishikawa R, Goto Y, Kojima S, Enokida H, Chiyomaru T, Kinoshita T, Sakamoto S, Fuse M, Nakagawa M, Naya Y, et al: Tumor-suppressive microRNA-29s inhibit cancer cell migration and invasion via targeting LAMC1 in prostate cancer. Int J Oncol 45: 401-410, 2014.
14. Goto Y, Nishikawa R, Kojima S, Chiyomaru T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa M, et al: Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer. FEBS Lett 588: 1973-1982, 2014.
15. Goto Y, Kojima S, Nishikawa R, Enokida H, Chiyomaru T, Kinoshita T, Nakagawa M, Naya Y, Ichikawa T and Seki N: The microRNA-23b/27b/24-1 cluster is a disease progression marker and tumor suppressor in prostate cancer. Oncotarget 5: 7748-7759, 2014.
16. Goto Y, Kurozumi A, Enokida H, Ichikawa T and Seki N: Functional significance of aberrantly expressed microRNAs in prostate cancer. Int J Urol 22: 242-252, 2015.
17. Nelson KM and Weiss GJ: MicroRNAs and cancer: Past, present, and potential future. Mol Cancer Ther 7: 3655-3660, 2008.
18. K ikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki N: miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HS CC). Br J Cancer 103: 877-884, 2010.
19. Fukumoto I, Hanazawa T, Kinoshita T, Kikkawa N, Koshizuka K, Goto Y, Nishikawa R, Chiyomaru T, Enokida H, Nakagawa M, et al: MicroRNA expression signature of oral squamous cell carcinoma: Functional role of microRNA-26a/b in the modulation of novel cancer pathways. Br J Cancer 112: 891-900, 2015.
20. Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 10: 687-692, 2001.
21. S andhu R, Rivenbark AG and Coleman WB: Loss of post-transcriptional regulation of DNMT3b by microRNAs: A possible molecular mechanism for the hypermethylation defect observed in a subset of breast cancer cell lines. Int J Oncol 41: 721-732, 2012.
22. Börno ST, Fischer A, Kerick M, Fälth M, Laible M, Brase JC, Kuner R, Dahl A, Grimm C, Sayanjali B, et al: Genome-wide DNA methylation events in TMPRSS 2-ERG fusion-negative prostate cancers implicate an EZH 2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2: 1024-1035, 2012.
23. K oh CM, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S and De Marzo AM: Myc enforces overexpression of EZH 2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget 2: 669-683, 2011.
24. Lin Y, Chen H, Hu Z, Mao Y, Xu X, Zhu Y, Xu X, Wu J, Li S, Mao Q, et al: miR-26a inhibits proliferation and motility in bladder cancer by targeting HMGA1. FEBS Lett 587: 2467-2473, 2013.
25. Z hang B, Liu XX, He JR, Zhou CX, Guo M, He M, Li MF, Chen GQ and Zhao Q: Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH 2 in breast cancer. Carcinogenesis 32: 2-9, 2011.
26. Z hu Y, Lu Y, Zhang Q, Liu JJ, Li TJ, Yang JR, Zeng C and Zhuang S M: MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein. Nucleic Acids Res 40: 4615-4625, 2012.
27. S imon JA and Lange CA: Roles of the EZH 2 histone methyltransferase in cancer epigenetics. Mutat Res 647: 21-29, 2008.
28. S parmann A and van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846-856, 2006.
29. Raman JD, Mongan NP, Tickoo SK, Boorjian SA, Scherr DS and Gudas LJ: Increased expression of the polycomb group gene, EZH 2, in transitional cell carcinoma of the bladder. Clin Cancer Res 11: 8570-8576, 2005.
30. K leer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF, et al: EZH 2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci US A 100: 11606-11611, 2003.
31. V arambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, et al: The polycomb group protein EZH 2 is involved in progression of prostate cancer. Nature 419: 624-629, 2002.
32. Fu X, Meng Z, Liang W, Tian Y, Wang X, Han W, Lou G, Wang X, Lou F, Yen Y, et al: miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis. Oncogene 33: 4296-4306, 2014.
33. H eo I, Joo C, Cho J, Ha M, Han J and Kim VN: Lin28 mediates the terminal uridylation of let-7 precursor MicroRNA. Mol Cell 32: 276-284, 2008.
34. V iswanathan SR, Daley GQ and Gregory RI: Selective blockade of microRNA processing by Lin28. Science 320: 97-100, 2008.
35. H agan JP, Piskounova E and Gregory RI: Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol 16: 1021-1025, 2009.
36. Piskounova E, Polytarchou C, Thornton JE, LaPierre RJ, Pothoulakis C, Hagan JP, Iliopoulos D and Gregory RI: Lin28A and Lin28B inhibit let-7 microRNA biogenesis by distinct mechanisms. Cell 147: 1066-1079, 2011.
37. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J and Tang DG: Distinct microRNA expression profiles in prostate cancer stem/ progenitor cells and tumor-suppressive functions of let-7. Cancer Res 72: 3393-3404, 2012.
38. Nadiminty N, Tummala R, Lou W, Zhu Y, Shi XB, Zou JX, Chen H, Zhang J, Chen X, Luo J, et al: MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth. PLoS One 7: e32832, 2012.
39. Xie C, Huang L, Xie S, Xie D, Zhang G, Wang P, Peng L and Gao Z : LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma. J Transl Med 11: 272, 2013.
40. Mura M, Hopkins TG, Michael T, Abd-Latip N, Weir J, Aboagye E, Mauri F, Jameson C, Sturge J, Gabra H, et al: LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression. Oncogene: Dec 22, 2014. doi.org/10.1038/ onc.2014.428 (Epub ahead of print).
41. Tcherkezian J, Cargnello M, Romeo Y, Huttlin EL, Lavoie G, Gygi SP and Roux PP: Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5'TOP mRNA translation. Genes Dev 28: 357-371, 2014.
42. Meyuhas O and Kahan T: The race to decipher the top secrets of TOP mRNAs. Biochim Biophys Acta: Sep 16, 2014. doi: 10.1016/j.bbagrm.2014.08.015 (Epub ahead of print).
43. Aoki K, Adachi S, Homoto M, Kusano H, Koike K and Natsume T: LARP1 specifically recognizes the 3' terminus of poly(A) mRNA. FEBS Lett 587: 2173-2178, 2013.
44. Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, et al: Pathway-based identification of biomarkers for targeted therapeutics: Personalized oncology with PI3K pathway inhibitors. Sci Transl Med 2: 43ra55, 2010.